Equities analysts expect that bluebird bio Inc (NASDAQ:BLUE) will report ($3.81) earnings per share (EPS) for the current quarter, according to Zacks. Nine analysts have made estimates for bluebird bio’s earnings, with estimates ranging from ($4.11) to ($3.02). bluebird bio reported earnings of ($2.72) per share during the same quarter last year, which indicates a negative year over year growth rate of 40.1%. The firm is scheduled to announce its next quarterly earnings report on Thursday, February 20th.
On average, analysts expect that bluebird bio will report full year earnings of ($13.91) per share for the current year, with EPS estimates ranging from ($14.38) to ($11.89). For the next year, analysts expect that the company will report earnings of ($15.01) per share, with EPS estimates ranging from ($17.37) to ($12.89). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow bluebird bio.
A number of equities analysts have recently commented on the stock. Bank of America assumed coverage on shares of bluebird bio in a report on Monday, February 3rd. They set a “buy” rating and a $120.00 price target on the stock. Oppenheimer upgraded shares of bluebird bio from a “market perform” rating to an “outperform” rating and set a $135.00 price target on the stock in a report on Thursday, December 12th. Leerink Swann upgraded shares of bluebird bio from a “market perform” rating to an “outperform” rating and set a $119.00 price target on the stock in a report on Tuesday, November 26th. Evercore ISI upgraded shares of bluebird bio from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $86.00 to $100.00 in a report on Monday, February 3rd. Finally, Wells Fargo & Co cut their price target on shares of bluebird bio from $242.00 to $160.00 and set an “overweight” rating on the stock in a report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $133.61.
In other bluebird bio news, CEO Nick Leschly sold 10,163 shares of bluebird bio stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $89.97, for a total value of $914,365.11. Following the completion of the sale, the chief executive officer now directly owns 56,712 shares of the company’s stock, valued at $5,102,378.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Philip D. Gregory sold 1,800 shares of bluebird bio stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $94.31, for a total transaction of $169,758.00. Following the completion of the sale, the insider now directly owns 30,892 shares of the company’s stock, valued at $2,913,424.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,727 shares of company stock valued at $1,242,889. Insiders own 3.00% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Rational Advisors LLC increased its stake in bluebird bio by 532.3% in the third quarter. Rational Advisors LLC now owns 392 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 330 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in shares of bluebird bio during the fourth quarter worth about $47,000. Whittier Trust Co. increased its position in shares of bluebird bio by 36.5% during the fourth quarter. Whittier Trust Co. now owns 542 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 145 shares in the last quarter. NuWave Investment Management LLC increased its position in shares of bluebird bio by 398.7% during the third quarter. NuWave Investment Management LLC now owns 788 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 630 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its position in shares of bluebird bio by 2,020.0% during the third quarter. Nisa Investment Advisors LLC now owns 1,060 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 1,010 shares in the last quarter.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Featured Article: Cost of Goods Sold (COGS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.